featured
Value of Plasma Cell–Depleting Escalation Therapies for Patients With Treatment-Refractory Severe Autoimmune Encephalitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical characteristics, treatments, outcome, and prognostic factors of severe autoimmune encephalitis in the intensive care unit: Standard treatment and the value of additional plasma cell-depleting escalation therapies for treatment-refractory patients
Eur. J. Neurol. 2022 Sep 29;[EPub Ahead of Print], L Schwarz, N Akbari, H Prüss, A Meisel, F ScheibeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.